An observational study in Atrial Fibrillation and Strokes Thrombotic, sponsored by Wuhan Asia Heart Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-12.
Sponsored by Wuhan Asia Heart Hospital · Observational
This is a sigle-center, prospective study to evaluate the role of D-Dimer testing in patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy.
Patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy was screened and signed to two group: Dabigatran group and Warfarin group. D-dimer test was analyzed before and 3 months after anticoagulation starting specificly. Patients were followed-up for at least 12 months,and clinical outcomes, including thrombotic events major bleeding events and all-cause deaths were recorded during follow-up period.
Patients with Non-valvular atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy.
Exclusion Criteria:
Patiets with atrial fibrillation received dabigatran (110mg, bid).
Drug: Dabigatran Etexilate 110mg
Patiets with atrial fibrillation received warfarin (110mg, bid).The target international normalized ratio (INR):1.6-3.0
Drug: Warfarin Sodium
Dabigatran Etexilate 110mg, BID
Also known as: Pradaxa
Target INR:1.6-3.0
Cardiovascular events
Thrombotic events, cardiovascular deaths, major bleeding events
Time frame: 12 months
Plan to share: Undecided — We will share the IPD after the paper being published
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wuhan Asia Heart Hospital